Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Clinical trial NCT03936153 · RECRUITING
Trial details
- NCT number
- NCT03936153
- Sponsor
- Xynomic Pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-20
- Primary completion
- 2026-07-31
- Enrollment
- 170
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.